目的:研究磷酸化蛋白激酶B(p-Akt)-雷帕霉素靶蛋白(mTOR)-p70核糖体蛋白S6激酶(p70S6K)信号通路中的p-Akt,mTOR和p70S6K 3种蛋白与卵巢癌临床病理特征及化学药物治疗(简称化疗)耐药的关系.方法:采用免疫组织化学方法检测18例卵巢癌化疗耐药和25例化疗敏感组织中p-Akt,mTOR和p70S6K蛋白的表达,分析这些蛋白与卵巢癌临床病理特征及化疗耐药的相关性.结果:p-Akt蛋白在卵巢浆液性癌、黏液性癌和子宫内膜样癌中的表达分别为77.14%,50.00%和66.67%,三者比较差异无统计学意义(P>0.05);在高、中分化和低分化癌中的表达分别为73.33%和75.00%,两者比较差异无统计学意义(P>0.05);在Ⅰ~Ⅱ期和Ⅲ~Ⅳ期中的表达分别为18.18%和93.75%,差异有统计学意义(P<0.05).mTOR蛋白在卵巢浆液性癌、黏液性癌和子宫内膜样癌中的表达分别为77.14%,100.00%和83.33%,三者比较差异无统计学意义(P>0.05);在高、中分化和低分化癌中的表达分别为80.00%和78.57%,两者比较差异无统计学意义(P>0.05);在Ⅰ~Ⅱ期和Ⅲ~Ⅳ期中的表达分别为27.27%和96.88%,差异有统计学意义(P<0.05).p70S6K蛋白在卵巢浆液性癌、黏液性癌和子宫内膜样癌中的表达分别为80.00%,100.00%和100.00%,三者比较差异无统计学意义(P>0.05);在高、中分化和低分化癌中的表达分别为93.33%和78.57%,两者比较差异无统计学意义(P>0.05);在Ⅰ~Ⅱ期和Ⅲ~Ⅳ期中的表达分别为45.45%和96.88%,差异有统计学意义(P<0.05).P-Akt蛋白在卵巢癌化疗耐药和敏感组织中的表达率分别为88.89%及64.00%;mTOR蛋白在耐药和敏感组织中的表达率分别为94.44%及68.00%;p70S6K蛋白在耐药和敏感组织中的表达率分别为100.00%及72.00%,3种蛋白在耐药组中的表达均高于敏感组(P<0.05).结论:p-Akt-mTOR-p70S6K信号通路中的3种蛋白可能参与卵巢癌的侵袭和转移,这3种蛋白的表达上调可能与卵巢癌化疗耐药有关,在临床上可作为预测卵巢癌化疗耐药的标志.%Objective:To study the relationship between alpha seine/threonine-protein kinase (p-Akt)-serine/ threonine-protein kinase (mTOR)-ribosomal protein S6 kinase (p70S6K) signaling pathway and clinicopathological features or chemoresistance of ovarian cancer.Methods:We checked the p-Akt,mTOR and p70S6K protein levels in 18 tissues with chemoresistance or 25 with chemosensitivity of ovarian cancer by immunohistochemistry technique,and analyzed the relationship between those proteins and clinicopathological features or chemoresistance of ovarian cancer.Results:The levels of p-Akt protein in ovarian serous carcinoma,mucinous carcinoma and endometrioid carcinoma were 77.14%,50.00% and 66.67%,respectively,with no significant difference (P>0.05).The levels of these proteins in well-middle differentiated carcinoma and low differentiated carcinoma were 73.33% and 75.00%,respectively,with no significant difference (P>0.05).The levels of these proteins in Ⅰ-Ⅱ stage carcinoma,and Ⅲ-Ⅳ stage carcinoma were 18.18% and 93.75%,respectively,with significant difference (P<0.05).The levels ofmTOR protein in ovarian serous carcinoma,mucinous carcinoma and endometrioid carcinoma were 77.14%,100.00% and 83.33%,respectively,with no significant difference (P>0.05).The levels of this protein in well-middle differentiated carcinoma and low differentiated carcinoma were 80.00% and 78.57%,respectively,with no significant difference (P>0.05).The levels of this protein in Ⅰ-Ⅱ stage carcinoma,and Ⅲ-Ⅳ stage carcinoma were 27.27% and 96.88%,respectively,with significant difference (P<0.05).The levels of p70S6K protein in ovarian serous carcinoma,mucinous carcinoma and endometrioid carcinoma were 80.00%,100.00% and 100.00%,respectively,with no significant difference (P>0.05).The levels of this protein in well-middle differentiated carcinoma and low differentiated carcinoma were 93.33% and 78.57%,respectively,with no significant difference (P>0.05).The levels of this protein in Ⅰ-Ⅱ stage carcinoma,and Ⅲ-Ⅳ stage carcinoma were 45.45% and 96.88%,respectively,with significant difference (P<0.05).The levels of p-Akt protein in tissue of chemoresistance and chemosensitivity of ovarian cancer were 88.89% and 64.00%,respectively,with significant difference (P<0.05).The levels of mTOR protein in tissue of chemoresistance and chemosensitivity of ovarian cancer were 94.44% and 68.00%,respectively,with significant difference (P<0.05).The levels of p70S6K protein in tissue of chemoresistance and chemosensitivity of ovarian cancer were 100.00% and 72.00%,respectively,with significant difference (P<0.05).Conclusion:The p-Akt-mTOR-p70S6K signaling pathway may take part in invasion and metastasis of ovarian cancer.The up-regulation of these proteins may be associated with the chemoresistance of ovarian cancer,and these proteins may have potential to be the prognostic markers for the chemoresistance of ovarian cancer.
展开▼
